Eye Disease News and Research

RSS

Eye diseases are widespread around the globe. According to the World Health Organization, the most important three eye diseases or conditions that are a potential threat to the global population are diabetic retinopathy, glaucoma, and age-related macular degeneration. One more vital reason for visual harm is refractive errors. Some of the important reasons for vision loss or low vision are age, healthcare, gender, genetic problems and the prevalence of family history.

SERI selects AB SCIEX TripleTOF 5600 system to test chronic eye inflammations

AB SCIEX, a global leader in life science analytical technologies, today announced that the Singapore Eye Research Institute, an internationally known eye research center, will advance biomarker candidates it identified for chronic inflammatory eye conditions into large-scale clinical trials for validation with the AB SCIEX TripleTOF™ 5600 System.

20 Apr 2011

Older women with high vitamin D status less likely to have early AMD

Women under the age of 75 with high vitamin D status were less likely to have early age-related macular degeneration, the leading cause of irreversible vision loss in adults, a University at Buffalo study has shown. The disease affects approximately 9 percent of Americans aged 40 and older.

12 Apr 2011

Study: Patients with glaucoma experience psychological problems

Fear of the unknown is one of the greatest issues facing patients with glaucoma - the second leading cause of blindness worldwide after cataracts - according to research in the April issue of the Journal of Advanced Nursing. People also worry about how the eye disease, which can be hereditary, will affect other members of their family.

11 Apr 2011

Bayer, Regeneron initiate two VEGF Trap-Eye Phase 3 trials in Diabetic Macular Edema

Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced that they have initiated the first of two Phase 3 clinical trials evaluating the efficacy and safety of VEGF Trap-Eye, an investigational new agent for the treatment of certain eye diseases, in the treatment of Diabetic Macular Edema.

8 Apr 2011

Optometrists congratulate Ontario government for progressive health policy

Ontarians will enjoy better access to eye health care now that optometrists can prescribe medications for sight-threatening conditions like eye infections and glaucoma.

7 Apr 2011

Scientists identify biological pathways that mediate IgA nephropathy

For the first time, researchers have found five regions in the human genome that increase susceptibility to immunoglobulin A nephropathy, a major cause of kidney failure worldwide - systematically identifying those that point to a tendency for IgA nephropathy, or a protection against it.

6 Apr 2011

Merck enters definitive agreement to acquire Inspire

Merck, known as MSD outside the United States and Canada, and Inspire Pharmaceuticals, Inc. today announced that they have entered into a definitive agreement under which Merck will acquire Inspire, a specialty pharmaceutical company focused on developing and commercializing ophthalmic products.

6 Apr 2011

IOVS journal publishes first global consensus report on MGD

The first global consensus report on meibomian gland dysfunction - a major cause of lid disease and evaporative dry eye - has been published in a special issue of the Investigative Ophthalmology & Visual Science journal.

1 Apr 2011

Study: People who have survived diabetes for many decades exhibit few complications

Over time, diabetes can wreak havoc on the body's eyes, cardiovascular system, kidneys and nerves. A major study by Joslin Diabetes Center researchers, however, has found that some people who have survived diabetes for many decades exhibit remarkably few complications—a discovery that points toward the presence of protective factors that guard against the disease's effects.

31 Mar 2011

SARcode's SAR 1118 Phase 2 data against dry eye to be presented at ARVO meeting

SARcode Corporation announced today that clinical data for their lead compound, SAR 1118, has been accepted for presentation during the upcoming Association for Research in Vision and Ophthalmology Annual Meeting being held May 1–May 5, 2011, in Fort Lauderdale, Florida.

25 Mar 2011

Eating fish protects from blindness: Study

According to latest study fish that is rich in omega 3 fatty acids significantly lowers the risk of developing age-related macular degeneration that leads to blindness. The study was published in the Archives of Ophthalmology.

17 Mar 2011

FDA accepts Merck's SAFLUTAN NDA for standard review

Merck, known as MSD outside the United States and Canada, announced today that the New Drug Application for SAFLUTAN, Merck's investigational preservative-free prostaglandin analogue ophthalmic solution, has been accepted for standard review by the U.S. Food and Drug Administration.

10 Mar 2011

Medwell commits $2,000,000 investment in Mimetogen

Medwell Capital Corp. today announced that it has committed to invest up to $2,000,000 in Mimetogen Pharmaceuticals Inc. ("Mimetogen"), a privately-held, clinical-stage company developing a treatment for dry eye disease. Medwell Capital participated in a Series B equity financing with existing Mimetogen investors, iNovia Capital, MSBi Valorisation and VIMAC Milestone Medica.

25 Feb 2011

Early diagnosis can delay or halt progression of macular degeneration

February is Age-related Macular Degeneration and Low Vision Awareness month, providing an opportunity to inform and educate the public on the leading cause of vision loss for adults over the age of 65. Today, over 15 million of these adults suffer from age-related macular degeneration, a number that is expected to grow considerably as the baby boomer generation begins heading into retirement age. While the risks are growing, awareness and education is key to treating and saving the eyesight of millions.

19 Feb 2011

Inspire fourth quarter revenues increase 2% to $30.3 million

Inspire Pharmaceuticals, announced today financial results for the fourth quarter and year ended December 31, 2010. For the quarter ended December 31, 2010, the Company reported a net loss of $4.3 million, or per common share, compared to a net loss of $2.6 million, or per common share, for the same period in 2009.

17 Feb 2011

Obesity associated with decreased risk of open-angle glaucoma in women, not men

Obesity may be associated with higher eye pressure and a decreased risk of open-angle glaucoma in women but not men, according to a report posted online today that will appear in the May issue of Archives of Ophthalmology, one of the JAMA/Archives journals.

14 Feb 2011

OXiGENE, NCI/CTEP and GOG collaborate on ZYBRESTAT Phase 2 study in relapsed ovarian cancer

OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that it has entered into a Cooperative Research and Development Agreement with the National Cancer Institute's (NCI) Cancer Therapy Evaluation Program (CTEP) to collaborate on the conduct of a randomized Phase 2 trial of ZYBRESTAT in combination with bevacizumab in patients with relapsed ovarian cancer.

14 Feb 2011

CVVS scientist receives top UK award for ground-breaking research on vascular stem cells, eye disease

One of Northern Ireland's leading scientists has received a top UK award, to support ground-breaking research into vascular stem cells and eye disease at Queen's University.

5 Feb 2011

Doctors of Optometry troubled by disregard for vision and eye health needs of children

The American Optometric Association, the voice of America's family eye doctors, today warned that if a set of U.S. Preventive Services Task Force recommendations are adopted as policy, significant harm will be caused to the ongoing efforts of eye doctors nationwide to reverse the high rates of preventable vision loss in children across America, from the first year of life through age 5.

5 Feb 2011

Queen’s scientist awarded Royal Society Wolfson Research Merit Award

One of Northern Ireland's leading scientists has received a top UK award, to support ground-breaking research into vascular stem cells and eye disease at Queen's University.

4 Feb 2011